Andrew Schiff - Profile and Investment Details

Investor Profile

Andrew Schiff is a Venture Capital, Private Equity Firm based in New York City, New York, United States with a diverse investment portfolio that includes companies such as Zeltiq Aesthetics, Dermira, Spruce Biosciences, Syros Pharmaceuticals, Asensus Surgical, Esperion Therapeutics, F2G, T2 BiosystemsEidos Therapeutics, Versartis, TRIA Beauty, Nuvation Bio, Xanodyne, Seragon Pharmaceuticals, Forge Biologics, Spirox, Verona Pharma, Avrobio, Talaris Therapeutics, Bioenvision, Miramar Labs, GTx, Zavante Therapeutics, Sirion Therapeutics, Cempra, Ambit Biosciences, CeNeRx BioPharma, Dren Bio, SkinMedica, BridgeBio, NextWave Pharmaceuticals, Pharmaron Holding, Topaz Pharmaceuticals Inc, Loxo Oncology, Elevation Oncology, Bridge Pharmaceuticals, Natural Dentist, Reneo Pharmaceuticals, Atreca, Aclaris Therapeutics, Promentis Pharmaceuticals, Agile Therapeutics, Biohaven Pharmaceutical, BioRelix, Cytos, Biomea Fusion, Ajax Health, Monte Rosa Therapeutics, ViewRay, Poseida Therapeutics, PowerVision, Cynapsus Therapeutics, VYNE Therapeutics, Cidara Therapeutics, Paratek Pharmaceuticals, Bristol-Myers Squibb, Aimmune Therapeutics, LensAR, Earlens Corporation, Arcus Biosciences, Roka Bioscience, ObsEva, Aragon Pharmaceuticals, Prolacta Bioscience, . Over time, Andrew Schiff has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Andrew Schiff is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Wellness, Women Founded, Equities, Rare Diseases, Healthcare Innovation, Life Science, Portfolio Management, Medical Technologies, Finance, Biotechnology, Medical Devices, Drug Development, Clinical Trials, Gene Therapy, Medical, B2B, Therapeutics, Health Tech, Pharmaceuticals, Oncology may find it worthwhile to explore potential connections with Andrew Schiff, as their portfolio suggests a familiarity and interest in this area.

Understanding Andrew Schiff’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.